Clinical trial · Interventional
Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies
A Prospective Phase II Study to Evaluate Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Indication: Patients with advanced lymphoid malignancies in the absence of an HLA identical or mismatch donor. Objectives: Overall survival at one year. Efficacy \>60%, rejection rate \<20%. Inclusion criteria: Age: 18-65 years old, no sibling or unrelated donor identified, low grade non-hodgkin lymphoma in third line (who already received at least one autologous transplantation); hodgkin lymphoma in early relapse (\<1 year), who received at least one autologous transplantation and sensible to chemotherapy and CLL with 17p deletion or in relapse less than 2 year after a fludarabine nbased regimen or in relapse after one autologous transplantation. Stem cell source: Two cord blood units containing both together more than 3x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Patients With Advanced Lymphoid Malignancies in the Absence of an HLA Identical or Mismatch Donor | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cord Blood Transplantation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Cord blood transplantation
- description
- Two cord blood units containing both together more than 3x10\^7 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients.
- interventionNames
- Other: Cord Blood Transplantation
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 1 year
Secondary outcomes (9)
- measure
- Engraftment
- timeFrame
- 100 days
- description
- Neutrophils \> 500/mm3 and platelets \> 20 Giga/L
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Age: 18-65 years old * no sibling or unrelated donor identified (9/10 or 10/10) * with either one of these advanced lymphoid malignancies 1. low grade non-hodgkin lymphoma in third line (who already received at least one autologous transplantation) 2. hodgkin lymphoma in early relapse (\<1 year)who received at least one autologous transplantation and sensible to chemotherapy 3. CLL with 17p deletion or in relapse less than 2 year after a fludarabine nbased regimen or in relapse after one autologous transplantation. Exclusion Criteria: * No patient signed consent * Previous allograft * Psychiatric conditions * HIV positive * HVC hepatitis requiring treatment * Previous total body irradiation (TBI) * Any contraindication to TBI * Any contraindication to allograft, such as cardiovascular, respiratory, renla or liver dysfunctions * No Health care insurance
References
Publications (0)
Data not yet available